Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

CellaVision, Audiocast, Q3'25

By Inderes11/6/2025, 10:00 AM
CellaVision

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Simon Østergaard
00:02 - 02:53

Thank you very much and thanks to everyone taking the time to listen to our quarterly report that we've launched this morning for our third quarter. I'm happy to say that I also have our interim CFO, Monica Johnson, with me, and we'll be happy to answer any questions you may have when we get to that part of the session. So the quarter in brief. And so we have named our quarterly report 'Softer Quarter' due to mixed regional performance. And this is also related to currency effects. We saw Americas and EMEA performing in line with expectations. We had some quarterly variations resulting in modest growth, which we're highlighting here. We are coming out with a quarter here where we are reporting net sales decreased by 1.7 percentage points to 176 million. However, due to the FX headwind of -4.3%, Then sales increased organically by 2.6% during this quarter compared to the comparable quarter last year. On the EBITDA side, we increased our EBITDA to 50 million. We increased our EBITDA by 1 million. And this corresponds to an EBITDA margin of 28%. Also, a small increase in terms of what we want to highlight with regards to our strategic direction and our progress. It's a very exciting time for the company and our partners, and we're highlighting the fact that we've completed our clinical trial. We've submitted our documentation to receive the CE mark for our bone marrow application. And so we do expect this one to be done according to plan. We aim to obtain the CE mark by early 2026. I think we've set Q1. So that's still in line, but we are positively optimistic about it, even though there are, of course, always risks with anything. But this is an exciting time. So now we are really looking into training and the commercial launch activities for 2026. Another significant portion of our investment has been allocated to upgraded software for our platforms, where we've completed the verification process and it is now being installed at customer sites for final validation before we roll it out, which is planned for the next quarter, specifically this quarter in November.

Unknown 1
02:56 - 02:57

All right.

Simon Østergaard
03:04 - 13:21

Here we go. Yes. And then there's a slide around the financial development. So, it's a busy slide. But what you have here are our Q3 numbers reported freshly at the very left-hand side, showing the comparable quarter. And then the year-to-date numbers for 2025 are in the middle, followed by the comparison to last year, and then the full year 2024 on the very right-hand side. So I talked about the organic growth and the revenue of 176. And if we sort of peel the onion and work our way through the P&L, that translates into a gross margin of 69%. So we increased the gross margin by a percentage point, and we had the full impact from our price increases during Q3. And we had a slight change in the product mix. So that was a positive contribution on the operating expense side of things. We invested 82 million, which went down compared to last year, a little on sales, a little on admin, and according to plan, we invested a bit more on the R&D side. So that actually translated into a growth in EBITDA of around two percentage points. So from 49 to 50 million, despite the negative decline in revenue on the R&D side, as you can see, 24% of sales is what we have invested into R&D. So we have invested a portion of our sales into R&D, which is, of course, slightly affected by sales. However, the investments are following our plan, and we've capitalized a little bit less than normal, only 14 million this quarter, which is primarily due to the vacation period and partly also the completion of the software upgrade, which also had a slight impact on how much we capitalized on the cash flow side of things. We had a cash flow before the working capital items of 52 million, and then the working capital adjustments or impact was actually -22 million. And the majority of that was from accounts receivable. Since we had quite a number of orders placed in September. So this is why our accounts receivable increased. So we had an operating cash flow of 29.6 million, 30 million. And on the investment side, we invested 22 million, both in the capitalized R&D activities as mentioned, but also investments in data storage were a significant chunk this year for server capacity for some of our new technologies. After subtracting our 4 million from finance activities, the cash flow related to that resulted in a total cash flow of 4 million. So that's really the story around our P&L. Let's take a look at the regional highlights. So in the Americas, we had 68 million on the top line coming from the Americas region, South and Northern America, which is equivalent to an organic growth of 4%. We also experienced a currency effect there, of course. I'd say in general it was carried by really good traction on the large instrument platforms and less from the smaller instruments where we saw a modest decrease. However, we also saw good traction in Latin America. So that is also positive for future growth. Generally, I'd say, when we look at our leading indicators in collaboration with our strategic partner, we believe that we have increasing potential in the US. This was also confirmed in the half-year report of Sysmex launched yesterday in EMEA. Likewise, sales amounted to 96 million compared to 98 million last year. That is organic growth of 1%. I think this was actually acceptable also in light of the fact that we were up against a pretty tough comparison since we had inventory build-up in the comparable quarter last year. So, a decent single-digit growth in reality. We had reagents growth as well. Quite a bit from EMEA. However, on the hematology side, the growth was modest, very modest, with only 1%. So there was some phasing of orders on the hematology side there, but generally a good 14% growth on the reagent business for APAC. I'd highlight that it was a soft quarter, with 13 million, reflecting 10% growth. But of course, on a very low base. This was also what we hinted at in our previous quarterly report where we had some inventory shipping. Since we are entering our program where we are manufacturing out of China. We shipped a considerable number of parts and instrument modules to China, which impacted sales. This was the main contributor to soft sales across APAC. We also sold outside of China. And so, we do see momentum in pockets across Southeast Asia and Australia. So that is a positive outlook there. And then I also want to emphasize that we are seeing good traction for improvement of revenue sales from our region in APAC. Of course, it's small numbers in APAC, but it gives us the confidence that our penetration and expansion in APAC on the region side is on the right track. If we cut the numbers in terms of sales per product group, the same numbers but sliced per product category, we have 93 million versus 102 on the instrument category. And again, the contribution from the last stage of large instruments was important. And then, as I just alluded to regarding the Made in China initiative, it is very important for us to be able to participate in the market in China by manufacturing our instruments there. So that is a project that is finally also coming to an end as part of our strategy on the reagent side. I mentioned the growth of 40 million in revenue versus the 35. So that's the 14% growth. It's good to see that what we define as non-hematology is actually contributing with a decent single-digit healthy growth this quarter. So that is really good. And then finally, on the software side, we recorded 43 million in revenue. So that is also a correlation with how we're doing on the instrument side, but it is actually a decent software revenue we accomplished. We also had a contribution coming from spare parts and consumables, worth 23 million. The key takeaways are that, as we say, yes, we've had a somewhat softer quarter with some different variations across the regions. But the underlying business is healthy, supported by the gradually expanding strategic partnership. Our focus and activities are really on training and commercial launch activities. And so, they will be here as we start the new calendar year. I also emphasized the software upgrade without going into details prior to launch. Then I would say that it is delivering a faster and smarter workflow, and it does have a new cutting edge user interface and user experience in terms of our fifth pillar in our strategic direction or strategy, the power of focus. We also have these new areas where we expand beyond hematology, which is really the focus of deploying our Fourier Ptychographic Microscopy technology, the FPM technology. And we have reported that we are integrating this into our next generation hematology analyzer, and that is proceeding according to plan. And based on this development, we're now also able to scan different sample formats in the context of cytology and pathology, as an example. And that is also an exciting area where we are having discussions with potential partners playing in those fields. Taken together, it has been a solid quarter. We worked hard. But also, the R&D and now the marketing side are ramping up. So, it's a pleasure to present the result today. And with that, I think we should open the floor for questions. Any questions are of course welcome. I also emphasized the software upgrade without going into details prior to launch.

Operator
13:23 - 13:42

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Simon Larsen from Danske Bank. Please go ahead.

Simon Larsen
13:44 - 14:04

Yes. Hi, Simon. I'd like to maybe start with a question on the software upgrade you announced is rolling out. Should we expect any financial impact from the rollout here already in Q4? And will this be sold as an option to the customers? Will it be mandatory? How will you charge for it? Yes. Any more details on the software upgrade would be helpful.

Simon Østergaard
14:06 - 14:57

I also emphasized the software upgrade without going into details prior to launch. The software upgrade is seen as an enhancement to our instruments, both in terms of usability and performance, to improve the workflow. We have decided that this will be part of the package. So when you purchase the bloodline, it will be included in the package. Why is this fixed as an example, then? This will not come with an additional fee for the end user. So this is really a means of differentiation. You should see this as a growth contributor by remaining relevant in the labs and demonstrating our innovation muscle. Prior to our next generation system. That's how you should look at it.

Simon Larsen
14:59 - 15:34

Um, why is this fixed as an example, then? Yeah, that's very clear. And also on the R&D CapEx here going forward, I think roughly the levels now, I'd say around 70 million per year are being capitalized. Should we expect this to decline going forward? As you know, the software product is now rolling out. The bone marrow product is being released. Of course, we've been investing in the next-generation instruments. I suppose, but how do you believe we should look at the capitalized R&D here in the coming, let's say, 1 or 2 years? Should it decline more to a historic level, or should it be kept roughly at the same level?

Simon Østergaard
15:35 - 16:44

Our aspiration is really to maintain focus on us being an innovation leader or an innovative company. I think we are at a pretty decent level. Here on the capitalization, we have a portfolio of projects we want to start. So this is also a bandwidth question for us. I think we're at a reasonable level. As we see more of our projects being terminated, it is a balance as to how mature our new projects are that we are capitalizing or if they are more immature than that. So you may see some changes in our capitalization, but our intention is actually to continue investing in the R&D phase. And we expect that as we see more changes also throughout next year. We'll probably provide more guidance on how we see it as we've come to the end of our focus period. So we will certainly be more specific around this particular question as we enter 2026.

Simon Larsen
16:45 - 17:23

Yeah, I think that would be a good idea. I think just as you're now finishing up a few of these bigger projects, it'd be good to help us understand how we should look at this moving forward. Yeah, maybe the final one from my end. You mentioned, I think, that the cash flow was somewhat held back by an increased amount of orders placed towards the end of the Q3 quarter. Could we expect this dynamic to continue into Q4, i.e. Is how you enter Q4 looking good on that same trajectory, or was it just a matter of timing that ended up in late Q3 here? Order intake and delivery.

Simon Østergaard
17:26 - 17:42

That is simply the nature of the payment terms. When we receive the orders throughout September, that's why you see this fluctuation on accounts receivable. This time around, it's not a systemic issue per se. It's really a timing thing.

Simon Larsen
17:45 - 17:48

Could we expect this dynamic to have continued into Q4, i.e., Clear. Thank you very much. I guess I can learn.

Simon Østergaard
17:50 - 17:51

Thank you very much, Simon.

Operator
17:55 - 17:59

The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
18:02 - 18:45

Thank you very much. And a few questions on my end. Starting off with the product mix and the gross margin, you mentioned having a favorable product mix this quarter, improving margins. Because the margins are a bit higher than they've been before, and you're still sort of affected by negative effects in the quarters, can you help us decipher which segment is improving its margins?

Simon Østergaard
18:48 - 19:19

Yeah, I think so. Pricing was one element in terms of the mix. We still had a 14% growth on the reagent side, which actually pulls down the margin. We have a slightly lower margin on the reagent side compared to instruments and software. But that was still despite that, we had solid growth on the large instruments, which contributed to the 1% increase versus last year.

Ulrich Trattner
19:23 - 19:42

Yet, when I arrived, things were already in motion. Anyway, you look at it. If you split it up into two segments, like cell morphology systems or morphology systems and reagent cells, some of these segments have improved their gross margin sequentially and year over year.

Simon Østergaard
19:46 - 19:54

Yes, yes. So help me out here. Like what? What are you looking for specifically? Which product group is it that you're referring to?

Ulrich Trattner
19:56 - 20:11

I'm just trying to figure out which aspect of the product mix has increased in margin. Regardless of the mix, some of your systems or reagents have increased their margins sequentially. And I'm just trying to figure out which part of it is moving the needle.

Simon Østergaard
20:11 - 20:32

Yeah, I think maybe this time around, we probably have more contribution from larger systems versus the smaller ones. So that has been a contributor, positively affecting the overall gross margin. I'd say that's the most likely driver you're looking for.

Ulrich Trattner
20:33 - 21:01

Yeah. That's great, thanks. And the software upgrades delivered here in November enable you to commercialize a wider range of MCD reagents. Have you received any feedback from customers? And can you just give us the highlights here of how you intend to commercialize that in the near-term? Will it be initial customer feedback followed by a gradual ramp-up, or how should we view this?

Simon Østergaard
21:02 - 22:27

Yes, that's a great question. No, you're absolutely right that the software upgrade also comes with the opportunity for changes to the smearing and staining device by Sysmex, which is called SB 50. So, that has also been upgraded so it can host our methanol-free stain. That's an important part of this integrated software upgrade. So that allows us now to actually start positioning methanol-free stains or Sysmex to position the methanol-free stains to be used on the SP 50, which is a major milestone. So we're in the phase of evaluating the stain with customers. I believe that Europe will be first. This is where we have the majority of our business, particularly with the classic stains. So there will, there can be some conversion, but obviously the value proposition of methanol-free is strong. So that can still contribute in Europe. And then it's also an enabler for the US. And we expect a launch in 2026. For the US, there are both customer assessments and certain regional preferences that we are working on finalizing. But we expect a launch to happen next year. That's kind of where we are for the US, right?

Ulrich Trattner
22:29 - 22:51

If we were to look at China, you've been working here, and we can read in the reports about transferring systems, and I guess it's Sysmex that is trying to build up manufacturing in China in order to participate in local tenders. So, where are they in terms of operations in China?

Simon Østergaard
22:54 - 23:38

We have a fixed site in China where we work together. So, we are manufacturing our devices for the Chinese market within China at their plant as part of this initiative. And they also have cell counters manufactured out of China. And as you rightfully say, that allows us to actually participate in hospital tenders or deals where it's a prerequisite to have Chinese-manufactured instruments. This is why this strategic initiative has been an important enabler for us to continue to compete in a more competitive market as opposed to elsewhere.

Ulrich Trattner
23:40 - 23:46

And are we to expect any long-term effects from this initiative?

Simon Østergaard
23:47 - 23:49

Sorry, can you repeat that again?

Ulrich Trattner
23:50 - 23:58

Are we supposed to expect any acceleration in China sales from this initiative in the near term?

Simon Østergaard
23:59 - 24:53

I think it's fair to be mindful. Also, if you read the report that came out yesterday from Sysmex, it is obvious that China is a fiercely competitive market to be in. However, this gives us the opportunity to actually compete in collaboration with China in that market. Protecting the market share that they report they have, and of course, aiming for growth via differentiation, is our game plan. But it is fierce, that we all know, that both on the pricing side and on the competitive side with local players, it is a difficult market, but it is relatively sizable for our APAC numbers, which is also why we have invested in this program to protect our position.

Ulrich Trattner
24:55 - 25:32

Okay, great. And last question on my end, building a little bit more on the capitalized R&D. It's down quite a lot sequentially. As you highlighted, the reported R&D is up due to the summer months; to what degree is this increase due to the summer months and prioritization? And how much of this is the pipeline maturing? The bone marrow application has now been submitted. What is left in terms of R&D spend for the bone marrow application, and since the software upgrade is also now a commercial product? So I guess that will not require that much R&D.

Simon Østergaard
25:33 - 27:00

No, that's true. I think after Q2, we also released some consultant costs or some consultants, which is also reflected in the reduced capitalization. And as you say, of course, the amount capitalized is equal to what we did last year, but coming from a higher base. So that is really because we are also releasing some consultants. Having said that, we are an innovation company. And I think that's super important, which is also what I tried to elaborate to Simon in the previous questions that were posed there. So, we are seeking opportunities to invest and maintain our strategic focus on differentiation. That would be unwise from a competitive position. But our intention is to really pursue our direction and stand by it. Part of your question was also related to bone marrow. We are confident as reported, and of course, there are risks, but we're confident that we are getting the CE mark for Europe. We still have investments to make to complete our trials and the work needed to enter the US. So we're not fully at a stable point, so to speak, with the investments related to bone marrow. That would be unwise from a competitive position.

Ulrich Trattner
27:01 - 27:05

That would be unwise from a competitive position. That was all the questions on my end. That would be unwise from a competitive position. Simon.

Simon Østergaard
27:05 - 27:06

Thanks, Ulrik.

Operator
27:10 - 27:14

The next question comes from Christian Li from Pareto Securities. Please go ahead.

Christian Li
27:16 - 27:40

That would be unwise from a competitive position. Good morning, and thank you for taking my questions. The first one is regarding the instrument sales that declined year on year, but your tone remains optimistic, especially for the larger systems. So, should we view this as an indication that strong demand will already lead to increased instrument sales in Q4?

Simon Østergaard
27:42 - 28:33

I would probably defer to be more specific. Regarding what happens in Q4. However, I do know that our leading indicators are positive. I do note that Sysmex, for the past two quarters, including the quarter they completed, reported yesterday, which corresponds to their Q1 and Q2 equivalent to calendar year Q2 and Q3. I do note that they are signaling or reporting instrument growth of 10% in the US and 4% in Europe. I think there is a healthy environment. This is also what we see. So, we are positively optimistic. So you read my tone correctly, but I will defer from being super specific until we've seen what orders we get in and so forth.

Christian Li
28:36 - 28:53

That would be unwise from a competitive position. Perfect. Demand for smaller instruments appears a bit softer than for the larger ones. Do you view this as a temporary situation? And what factors do you believe could drive a recovery in the near term?

Simon Østergaard
28:54 - 30:27

Yes, I think it's temporary. I think we, together with our partner, have pushed the concept. It included both smearing and staining, along with our DC One instruments, for the small labs. Prior to this, we had a very healthy double-digit growth on the DC one instruments sold by itself. And then we positioned this instrument package called the Diff Line. And it is no secret that we had some operational performance issues with the smear box. So, I truly believe that part of the issue is not the market demand. It's our product issue that we had. And now we do have another simple solution that can substitute. So it's a matter of getting aligned and getting back to really working with the opportunities because we have seen a glitch in the pipeline that was built up due to this. But I really trust that it's a temporary thing. Everyone. The demand is there. And also, if I look at it, especially in the US, all the chains are set up for our solution. And I do believe we're the only company that can actually serve that segment in a networked manner. From small labs integrated with the connectivity and our software solution to cater and be managed and decided upon from a diagnostic perspective at the large labs. So it's temporary.

Christian Li
30:28 - 30:43

Okay, great. My final question: regions performed really well with strong momentum in APAC. Do you see any risk of inventory buildup in the region that could dampen sales in the fourth quarter?

Simon Østergaard
30:45 - 31:38

No, you're right. I'd say inventory buildup. Then I'm thinking specifically about China. And the challenge there when you build up your own manufacturing is that, first of all, the line we are selling a lot into China is then sitting in a manufacturing line, and after that, you have a layer of 60 to 70 distributors below. There's very little transparency to the end user in China. From that perspective, I would probably answer that. Yes, there is a risk of some inventory build-up for the time being because it's very hard to ascertain how much is actually reaching the end users at this time. So there's a little bit of risk for that, specifically related to China.

Unknown 2
31:38 - 31:41

Perfect. Yeah. Great.

Christian Li
31:41 - 31:41

Thank you very much.

Simon Østergaard
31:42 - 31:43

Thanks, Christian.

Operator
31:47 - 31:51

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
31:53 - 32:21

Yes. Hi, Simon. I wanted to continue a bit on the last question about APAC instrument sales. So, of course, it was slower in Q3 due to some inventory destocking following the large Q2 order. But given that you now have local assembly in China, as I understand it, will this lead to APAC instruments becoming even more lumpy in the future? It has been lumpy historically as well, but could it become even more pronounced now?

Simon Østergaard
32:23 - 33:28

I think the lumpiness is primarily driven by China and not by APAC as a whole. So that's specifically for China, I would say. But temporarily, I can certainly not guarantee that there will not be some lumpiness. China. Sorry. APAC has always been quite lumpy. And also because China is the biggest market that we serve. However, I do see opportunities both when we look at Japan and when we look at Southeast Asia, particularly in Australia and New Zealand. So, some lumpiness can occur and that cannot be sort of neglected, so to speak. But still, I think it's positive that we're actually seeing opportunities both on the instrument side and also on the reagent side, where we believe there is a good opportunity to bundle our offerings because we are the only provider who can provide both instruments, software, and reagents.

Ludvig Lundgren
33:31 - 33:52

Okay, great. So yeah, just a follow-up to that. So you noticed 3 million in reagent sales in APAC during Q3. We've seen some spikes in reagent sales historically as well. Is this to be considered somewhat of a one-off at this level, or does it rather reflect that you are seeing a significant increase in reagent customers in the region?

Simon Østergaard
33:53 - 34:53

No, you're right. It's not a continuous sort of flow. There is lumpiness if you look at the revenue for APAC reagents per se. However, we do believe that the shipments we send go to multiple markets. So you should see it as a sign of us starting to actually grow the base of reagents being consumed across multiple markets in APAC. I think that's the positive thing. Additionally, we are working on our logistics setup to serve the reagent market in APAC, which is another driver that can help us facilitate and provide the reagents. So, you should expect growth, but I cannot guarantee that there will not be this lumpiness because it is a matter of large shipments that go when they go and sometimes they don't. So that's how you should look at it.

Ludvig Lundgren
34:55 - 35:18

There is lumpiness if you look at the revenue for APAC reagents per se. Do you understand? Very clear. Then another follow-up. Just consider the instrument sales in APAC. So on a rolling 12-month basis, I guess it has stabilized now around 25 to 27 million, something like that. Is this a fair level to extrapolate ahead, or do you expect this to grow? Sample looking into early 2026.

Simon Østergaard
35:20 - 35:22

For example, regarding the last part. I didn't hear that.

Ludvig Lundgren
35:23 - 35:33

Yes. So in 2026, do you expect to have a similar type or a similar amount of quarterly deliveries on an average level?

Simon Østergaard
35:33 - 36:21

Yeah, it's always tricky with the average question. I think it's a decent level. Having said that, there are specific opportunities. I'd say when we look into it and discuss with our partners. There are specific opportunities sitting in APAC that are significant, and if they don't come, then you end up with this relatively flat look. However, the spikes can certainly come because we have some good opportunities across networked hospitals both in Australia and New Zealand. But also in Japan. And if they materialize, then I think we should certainly expect growth when you do your math over 2026.

Ludvig Lundgren
36:24 - 36:43

There is variability if you look at the revenue for APAC reagents per se. There is volatility if you look at the revenue for APAC reagents per se. And like because I think last year we saw quite a significant spike in APAC instrument deliveries in Q4. Is there any seasonal component to that, where customers are trying to fill their budgets, or was that more of a one-off situation?

Simon Østergaard
36:43 - 37:11

We compared that with last year. What I recall is that we had to serve. We were obligated to serve a specific tender that was, you know, the type of thing from five years ago. So that happens in the comparable quarter. Q4 last year. I don't expect there to be much, you can call it seasonality per se. It's more a function of where the specific opportunities materialize rather than seasonality.

Ludvig Lundgren
37:14 - 37:32

Is there any seasonal component to that, you know, customers are trying to fill their budgets, or was that more of a one-off sort of thing? Like, is there any seasonal component to that, you know, customers trying to fill their budgets, or was that more of a one-off sort of thing? And then, final question. You've talked a bit before about reagent sales in the US and the potential there. Any updates on that? And if we could start to see, you know, this starting to ramp up in 2026 or. Yeah, just how should we think about that?

Simon Østergaard
37:33 - 38:51

Yeah. I think about it in a way where we've been, also at our capital market day, when we launched The Power of Focus, really emphasizing that the methanol-free stain is the enabler to penetrate the reagent market in the US. That assumption has not changed. But now we've progressed much further. So we're actually able to bring MacD onto the seismic smearing and staining device that is consuming our methanol-free stain. So, I think we've come a long way on the development side. So now it's about getting some customer feedback on the stain, whether there are any last tweaks needed. For us, I do expect it to materialize, let's say mid-2026, which of course means that the contribution from the reagent in 2026 US is not enormous, but it is significant milestone-wise. And the fact that we start launching this has an enormous impact also on how we work with the team over there. To actually position our total solution now, also including instruments. So, by the end of the day, these are very exciting times for us.

Ludvig Lundgren
38:54 - 38:57

Okay, yeah, I agree. Thanks a lot for taking my questions, I'll jump back.

Simon Østergaard
38:57 - 38:59

Thanks, Ludovic. Pleasure.

Operator
39:04 - 39:21

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Simon Østergaard
39:23 - 40:38

Thank you very much. And first of all, thanks to all of you for taking the time to listen in and for staying with us throughout the Q&A. In my closing comment, I want to especially thank our strategic partners and the partner organizations all across the regions and different functions. I really see gradual, constant progress here. One and a half years after, we specifically launched the strategic alliance agreement with the Sysmex Corporation and team. In particular, I want to thank our team and staff as it has been an extremely tough quarter, probably more than usual. And I think they know what I am referring to regarding the internal matters. However, the dedication and focus seem endless across all our functions. So, really a heartfelt piece of appreciation here. Finally, I want to emphasize that on February 5th, 2026, we will announce and present our year-end bulletin for 2025. So, that will be published. And we are very much looking forward to presenting the results. And with that, I thank you for your attention and your interest in our presentation. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…